Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.11.2022 | Case report

Cisplatin/durvalumab/gimeracil/oteracil/tegafur

Myelosuppression and thrombocytopenia: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Makiguchi T, et al. Immune-mediated thrombocytopenia induced with durvalumab after chemoradiotherapy in a non-small cell lung cancer patient: A case report. Thoracic Cancer 12: 2811-2814, No. 20, Oct 2021. Available from: URL: http://doi.org/10.1111/1759-7714.14106 Makiguchi T, et al. Immune-mediated thrombocytopenia induced with durvalumab after chemoradiotherapy in a non-small cell lung cancer patient: A case report. Thoracic Cancer 12: 2811-2814, No. 20, Oct 2021. Available from: URL: http://​doi.​org/​10.​1111/​1759-7714.​14106
Metadaten
Titel
Cisplatin/durvalumab/gimeracil/oteracil/tegafur
Myelosuppression and thrombocytopenia: case report
Publikationsdatum
01.11.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-28518-0

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Multiple drugs

Case report

Glipizide

Case report

Multiple drugs